At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 23 enrolled
Drug / intervention
rosiglitazone-metformin fixed dose combination +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of the Effects of Rosiglitazone and Glimepiride, Both Given in Combination With Metformin, on 24-Hour Glycemia in Type 2 Diabetes Patients Not Controlled With Metformin Alone. A 3-Month Multicentre, Randomized, Parallel-Group, Open-Label Study.
In Brief
A Phase 4 clinical trial evaluating rosiglitazone-metformin fixed dose combination and metformin + glimepiride for Non-Insulin-Dependent Diabetes Mellitus. Completed, enrolled 23 participants.
Detailed Summary
A better glycemic control is associated with less complications (cardiac diseases, blindness, etcetera) for type 2 diabetic patients. The objective is to study if rosiglitazone may lead to a more regular glycemic pattern with less hyperglycemia and hypoglycemia episodes than with a sulphonylurea (glimepiride).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Insulin-Dependent Diabetes Mellitus
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2005
First PostedApr 2006
Primary CompletionOct 2007
TodayJul 2026
First PostedApr 27, 2006
Enrollment StartNov 1, 2005
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 20.2 years ago
Interventions
rosiglitazone-metformin fixed dose combinationdrug
metformin + glimepiridedrug